SecBot SecBot

ANVS drug pipeline

Annovis Bio, Inc. · 1 rated drug
$0.7500
−19.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 Alzheimer's succeeds, NDA submission could come in early 2027 (symptomatic) or early 2028 (disease-modifying). Earliest potential FDA approval would be late 2028 at best.

buntanetap Updated Jul 10

What to watch

Investors should watch for the Q1 2027 Alzheimer's Phase 3 symptomatic readout as the defining catalyst. The company will likely need additional financing before then given ~$14M cash and ~$17M/quarter burn. The Parkinson's miss on ITT primary endpoint is a cautionary precedent. Analyst consensus is strong-buy with $11 mean PT, but that reflects binary-option-like upside rather than de-risked fundamentals.

Bull case
  • Differentiated mechanism: oral pill targeting multiple toxic proteins (not just amyloid), avoiding IV infusion burden and ARIA safety risks of approved antibodies (Leqembi, Kisunla).
  • Phase 2/3 Alzheimer's results published in Nature Portfolio (npj Dementia) April 2026 showed statistically significant cognitive improvements and favorable safety in mild-to-moderate AD patients.
  • Pivotal Phase 3 Alzheimer's trial fully enrolled (850 patients, exceeding projections) with DSMB safety approval, symptomatic readout on track for Q1 2027; NDA submission could follow shortly after.
Bear case
  • Parkinson's Phase 3 trial missed its primary endpoint in the total ITT population, a significant red flag that raises questions about efficacy consistency and trial design.
  • Cash position is precarious: $14.2M at Q1 2026 end (plus $10M raised in April 2026) vs. $17.6M quarterly net loss. Likely needs another dilutive offering before the Q1 2027 readout.
  • Alzheimer's disease is notoriously difficult, Phase 3 drugs have only a ~12% transition success rate from Phase 3 to registration per GlobalData.